Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
153.40
+2.26 (1.50%)
At close: Apr 14, 2026, 4:00 PM EDT
152.45
-0.95 (-0.62%)
After-hours: Apr 14, 2026, 7:13 PM EDT
Insmed Employees
Insmed had 1,664 employees as of December 31, 2025. The number of employees increased by 393 or 30.92% compared to the previous year.
Employees
1,664
Change (1Y)
393
Growth (1Y)
30.92%
Revenue / Employee
$364,437
Profits / Employee
-$767,293
Market Cap
33.11B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,664 | 393 | 30.92% |
| Dec 31, 2024 | 1,271 | 359 | 39.36% |
| Dec 31, 2023 | 912 | 176 | 23.91% |
| Dec 31, 2022 | 736 | 123 | 20.07% |
| Dec 31, 2021 | 613 | 92 | 17.66% |
| Dec 31, 2020 | 521 | 86 | 19.77% |
| Dec 31, 2019 | 435 | 62 | 16.62% |
| Dec 31, 2018 | 373 | 159 | 74.30% |
| Dec 31, 2017 | 214 | 53 | 32.92% |
| Dec 31, 2016 | 161 | 36 | 28.80% |
| Dec 31, 2015 | 125 | 36 | 40.45% |
| Dec 31, 2014 | 89 | 28 | 45.90% |
| Dec 31, 2013 | 61 | 20 | 48.78% |
| Dec 31, 2012 | 41 | -1 | -2.38% |
| Dec 31, 2011 | 42 | 2 | 5.00% |
| Dec 31, 2010 | 40 | 25 | 166.67% |
| Dec 31, 2009 | 15 | -82 | -84.54% |
| Dec 31, 2008 | 97 | 3 | 3.19% |
| Dec 31, 2007 | 94 | -63 | -40.13% |
| Dec 31, 2006 | 157 | 72 | 84.71% |
| Dec 31, 2005 | 85 | 30 | 54.55% |
| Dec 31, 2004 | 55 | 35 | 175.00% |
| Dec 31, 2003 | 20 | -3 | -13.04% |
| Dec 31, 2002 | 23 | -37 | -61.67% |
| Dec 31, 2001 | 60 | 20 | 50.00% |
| Dec 31, 2000 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Revolution Medicines | 883 |
INSM News
- 7 days ago - Insmed discontinues development of skin condition drug after mid-stage study miss - Reuters
- 7 days ago - Insmed Provides Clinical Update on Phase 2b CEDAR Study - PRNewsWire
- 22 days ago - Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path - Benzinga
- 22 days ago - Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease - PRNewsWire
- 5 weeks ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 7 weeks ago - Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update - PRNewsWire
- 2 months ago - Insmed To Present at March 2026 Investor Conferences - PRNewsWire
- 2 months ago - Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 - PRNewsWire